252 articles
Ulimorelin
Ulimorelin (TZP-101, LP101), a macrocyclic ghrelin receptor agonist prokinetic developed by Tranzyme Pharma for postoperative ileus; potent in phase 2b but failed phase 3 ULISES trials and was discontinued.
Ulinastatin
Ulinastatin (urinary trypsin inhibitor, UTI) is a Kunitz-type serine protease inhibitor glycoprotein from human urine, marketed in Asia for acute pancreatitis and studied in sepsis, cardiac surgery bleeding, and ARDS.
Umeclidinium
Umeclidinium (umeclidinium bromide, Incruse Ellipta) is a once-daily inhaled long-acting muscarinic antagonist at 62.5 mcg for COPD maintenance, also combined with vilanterol and fluticasone furoate in Anoro and Trelegy Ellipta.
Vercirnon
Vercirnon (CCX282-B, GSK1605786, Traficet-EN) is an oral small-molecule antagonist of chemokine receptor CCR9, developed for Crohn's disease; phase 3 SHIELD trials failed to show efficacy and development was terminated.
Vilanterol
Vilanterol (GW642444, vilanterol trifenatate) is a once-daily, 24-hour long-acting beta2 agonist bronchodilator from GSK, used only in combination inhalers: Breo/Relvar Ellipta, Anoro Ellipta, and Trelegy Ellipta for asthma and COPD.
Vonoprazan
Vonoprazan (TAK-438; Takecab, Voquezna) is a potassium-competitive acid blocker inhibiting gastric H+/K+-ATPase reversibly; approved in Japan 2014 and the US 2022 for GERD, erosive esophagitis, and H. pylori regimens.
Xiaoer Zibei Xuanfei Syrup
Xiaoer Zibei Xuanfei Syrup (小儿紫贝宣肺糖浆), also called Children's Zibei Xuanfei Syrup, is a traditional Chinese medicine syrup approved by China in 2023 for children's cough from acute bronchitis.
Xylometazoline
Xylometazoline (Otrivin) is an imidazoline alpha-adrenergic nasal decongestant developed in the late 1940s, acting within 5–10 minutes for up to 10 hours; UK use now limited to 5 consecutive days due to rebound congestion risk.
Yinqiao Qingre tablets
Yinqiao Qingre tablets (银翘清热片), also known as Yinqiao Baidu tablets, are a Class 1.1 TCM innovative drug by Jiangsu Kanion approved in November 2021 for wind-heat type common cold, the first such approval under China's 2020 registration classification.
Zafirlukast
Zafirlukast (Accolate) is an oral leukotriene receptor antagonist for chronic asthma prophylaxis in patients 5 years and older; FDA approved 1996, dosed 20 mg twice daily, with hepatotoxicity and warfarin interaction warnings.
Zhishi Total Flavonoids Tablets (Fructus Aurantii Immaturus total flavonoids)
Zhishi Total Flavonoids Tablets (枳实总黄酮片, Aulantai) is a class 1.2 innovative TCM from immature bitter orange, approved by NMPA in October 2023 for functional dyspepsia, made by Jiangxi Qingfeng and reimbursed nationally since 2025.
Zipeprol
Zipeprol (CAS 34758-83-3), a piperazine non-opioid antitussive sold as Respilene and Tusigen, was abused at high doses for hallucinogenic, opiate-like effects and placed in Schedule II of the 1971 Psychotropic Convention in 1995.